Latest stories on ALKS
Alkermes expects Q3 2026 total revenues of $450M-$470M as CEO transition and orexin readouts approach
Seeking Alpha56 · neutralearnings
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Piper Sandler raises Alkermes stock price target on pipeline value
Investing.com Analyst Ratings61 · neutralanalyst
Alkermes GAAP EPS of $0.00, revenue of $496M
Seeking Alpha56 · neutralearnings
Alkermes plc. (ALKS) files 8-K
SEC 8-K50 · neutralgeneral
Alkermes plc Reports Second Quarter 2026 Financial Results | ALKS Stock News
StockTitan50 · neutralearnings
Alkermes Q2 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
Stifel raises Alkermes stock price target on orexin program outlook
Investing.com Analyst Ratings61 · neutralanalyst
Alkermes to Report Second Quarter Financial Results on July 28, 2026 | ALKS Stock News
StockTitan50 · neutralgeneral
Alkermes Ends Generic VIVITROL Supply Agreement with Amneal
TipRanks48 · neutralgeneral
Alkermes plc. (ALKS) files 8-K
SEC 8-K50 · neutralgeneral
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Seeking Alpha67 · bullishm&a
Alkermes plummets on mid-stage alixorexton data for narcolepsy
Seeking Alpha28 · bearishproduct/pr
Alkermes Gains Orphan Status For Sleep Disorder Therapy
TipRanks63 · neutralproduct/pr
Alkermes plc. (ALKS) files 8-K
SEC 8-K50 · neutralgeneral
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | ALKS Stock News
StockTitan59 · neutralproduct/pr
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia
Seeking Alpha63 · neutralproduct/pr
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha55 · neutralgeneral
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | ALKS Stock News
StockTitan55 · neutralgeneral
ALKS: [8-K] Alkermes plc. Reports Material Event
StockTitan SEC50 · neutralgeneral